EUVIMEDEUVIMED entdecken
Crossref

B-cell lineage neoplasms transdifferentiating into histiocytic/dendritic cell neoplasms: diversity, differentiation lineage, genomic alterations, and therapy: Report from the 2021 SH/EAHP Workshop

Wenbin Xiao iD, Catalina Amador, James R Cook iD, Magdalena Czader, Sandeep Dave, Ahmet Dogan, Amy Duffield, John Goodlad iD, Reza Nejati, German Ott, Mariusz Wasik

American Journal of Clinical Pathology · 01.06.2023 · 159 (6) · 522-537

DOI: 10.1093/ajcp/aqad022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 11.04.2023. Verfasst von Wenbin Xiao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, US. Hauptthemen laut MEDLINE: Lymphoma, B-Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To report findings from the 2021 Society for Hematopathology/European Association for Haematopathology Workshop within the category of B-cell lineage neoplasms’ transdifferentiation into histiocytic/dendritic cell neoplasms (HDCNs).

Methods

The workshop panel reviewed 29 cases, assigned consensus diagnoses, and summarized findings.

Results

The specific diagnoses of transdifferentiated HDCN tumors were histiocytic sarcoma (16); Langerhans cell histiocytosis/sarcoma (5); indeterminate DC tumor (1); and HDCN, unclassifiable (1). Approximately one-third of the patients reviewed had follicular lymphoma; lymphoblastic leukemia/lymphoma; or another B-cell lymphoma, most commonly chronic lymphocytic leukemia/small lymphocytic lymphoma. There was a 3:1 preponderance toward women, median patient age was 60 years, and the median interval between the initial diagnosis of B-cell lineage neoplasm and HDCN was 4 to 5 years. The submitted cases have demonstrated substantial heterogeneity as well as overlapping immunophenotypic and other features. Comprehensive genomic DNA sequencing revealed alterations enriched in the MAPK pathway. Based on shared and distinct alterations seen in HDCNs and the preceding lymphomas, both linear and divergent clonal evolutionary pathways were inferred. Furthermore, RNA sequencing performed in a subset of cases yielded new insights into markers that could be useful for more precise cell lineage identification. The panel has thus proposed an updated algorithm for HDCN lineage assignment. The outcome of transdifferentiated HDCNs was poor, but the MAPK signaling pathway emerges as a potentially attractive therapeutic target.

Conclusions

Transdifferentiated HDCNs demonstrate heterogeneity and pose diagnostic challenges with regard to exact classification, but the in-depth characterization of the submitted cases have added to our understanding of the secondary HDCNs transdifferentiated from B-cell lymphoma/leukemia. Continuous efforts focusing on deciphering the specific cell lineage and differentiation state of these tumors will be critical for their accurate classification. Comprehensive molecular characterization of HDCNs may be informative in this regard. With the list of novel pharmacologic inhibitors of the MAPK pathway continuing to expand, improved outcomes for HDCN can be expected.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, B-CellLymphoma, FollicularLeukemia, Lymphocytic, Chronic, B-CellHumansFemaleMiddle AgedCell LineageCell DifferentiationGenomicsDendritic Cells

Stichwörter der Autor:innen

B-cell lymphomahistiocytic/dendritic cell neoplasmtransdifferentiation

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, US.
  • Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, US.
  • Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, US.
  • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, US.
  • Department of Medicine, Duke University School of Medicine, Durham, NC, US.
  • Department of Pathology, NHS Greater Glasgow and Clyde, Glasgow, UK.

ORCID-Profile: Wenbin Xiao, James R Cook, John Goodlad

Zitieren

APA

Xiao, W., Amador, C., Cook, J. R., Czader, M., Dave, S., Dogan, A., Duffield, A., Goodlad, J., Nejati, R., Ott, G., & Wasik, M. (2023). B-cell lineage neoplasms transdifferentiating into histiocytic/dendritic cell neoplasms: diversity, differentiation lineage, genomic alterations, and therapy: Report from the 2021 SH/EAHP Workshop. American Journal of Clinical Pathology, 159(6), 522-537. https://doi.org/10.1093/ajcp/aqad022

Vancouver

Xiao W, Amador C, Cook JR, Czader M, Dave S, Dogan A, et al. B-cell lineage neoplasms transdifferentiating into histiocytic/dendritic cell neoplasms: diversity, differentiation lineage, genomic alterations, and therapy: Report from the 2021 SH/EAHP Workshop. American Journal of Clinical Pathology. 2023;159(6):522-537. doi:10.1093/ajcp/aqad022

BibTeX
@article{Xiao2023,
  author = {Xiao, Wenbin and Amador, Catalina and Cook, James R and Czader, Magdalena and Dave, Sandeep and Dogan, Ahmet and Duffield, Amy and Goodlad, John and Nejati, Reza and Ott, German and Wasik, Mariusz},
  title = {B-cell lineage neoplasms transdifferentiating into histiocytic/dendritic cell neoplasms: diversity, differentiation lineage, genomic alterations, and therapy: Report from the 2021 SH/EAHP Workshop},
  journal = {American Journal of Clinical Pathology},
  year = {2023},
  volume = {159},
  number = {6},
  pages = {522--537},
  doi = {10.1093/ajcp/aqad022}
}
Kostenlos starten →